In 2012, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published a position statement on the management of hyperglycemia in patients with type 2 diabetes. This was needed because of an increasing array of anti hyperglycemic drugs and growing uncertainty regarding their proper selection and sequence. The ADA and EASD have requested an update to the position statement incorporating new data from recent clinical trials. The Writing Group reconvened to discuss the changes. An entirely new statement was felt to be unnecessary. Instead, the group focused on those areas where revisions were suggested by a changing evidence base. This briefer article should therefore be read as an addendum to the previous full account.